PLK1 protects against sepsis-induced intestinal barrier dysfunction.

Area of Science:

• Cell Biology
• Molecular Biology
• Gastroenterology

Background:

• Sepsis frequently causes intestinal barrier dysfunction in intensive care units, leading to high mortality.
• Intestinal barrier integrity is crucial for preventing pathogen translocation and systemic inflammation.

Purpose of the Study:

• To investigate the role of Polo-like kinase 1 (PLK1) in ameliorating sepsis-induced intestinal barrier dysfunction.
• To determine if PLK1 can protect intestinal epithelial cells from sepsis-related damage.

Main Methods:

• Lipopolysaccharide (LPS) was used to induce sepsis models in mice and HT-29 intestinal epithelial cells.
• Assessed intestinal barrier disruption, apoptosis, and proliferation in response to LPS and PLK1 levels.
• Investigated the effect of PLK1 overexpression on LPS-induced cellular damage.

Main Results:

• LPS injection disrupted the mouse intestinal barrier, causing apoptosis and inhibiting proliferation of intestinal epithelial cells, with decreased PLK1.
• LPS stimulation in HT-29 cells induced apoptosis and inhibited proliferation, mirroring in vivo findings.
• Overexpression of PLK1 partially rescued HT-29 cells from LPS-induced apoptosis and proliferation inhibition.
• LPS reduced PLK1 levels, leading to intestinal epithelial barrier dysfunction.

Conclusions:

• Reduced PLK1 levels contribute to sepsis-induced intestinal epithelial cell apoptosis and proliferation inhibition, disrupting the intestinal barrier.
• PLK1 plays a protective role against sepsis-induced intestinal barrier dysfunction.
• PLK1 represents a potential therapeutic target for treating sepsis-associated intestinal barrier dysfunction.